Ipsen Pharma S.a.s.

Societe De Conseils De Recherches Et D'applications Scientifiques (s.c.r.a.s.)

Societe De Conseils De Recherches Et D'applications Scientifiques Sas

Commissariat a L'energie Atomique

Centre National De La Recherche Scientifique

Societe De Conseils De Recherches Et D'applications Scientifiques

Ipsen Biopharm Limited

Le Centre National De Recherche Scientifique (cnrs)

Ipsen Limited

Ipsen Pharma

Roland Cherif-Cheikh

Didier Bourissou

Christophe Aubert

Blanca Martin-Vaca

Martin Montes

Thierry Rimlinger

Fabrice Bonacci

Serge Barneaud

Zheng Xin Dong

Jean-Christophe Cintrat

Bernard Rousseau

Chantal Roume

Joël Richard

Frédéric Ben

Anne-Paula De Sousa Delgado

Frédéric Lacombe

Magalie Graullier

Marie-Thérèse Paternostre

Céline Valery

Thomas Ciaran Loughman

Franck Artzner

Matthew Egerton Young

Jacques-Pierre Moreau

Jean-Bernard Cazaux

Stéphane Roux

Anca Dumitrescu

Frederic Lacombe

Pierre Bernard D'Arbigny

John F Batchelor

Aurelie Alba

Fabien Jeannerot

Melinda Ligeti

Anne Petit

Isabel Diaz Del Consuelo

Marie Delporte

Anne Brochard

Ruth Bielsa Guivernau

Anne De Sousa Delgado

Laurence Lachamp

Chris Dott

Resurreccion Alloza Miravete

Julie Fournes

Maarten Ijsselstijn

Jose-Antonio Cordero Rigol

Maria Dolores Tobalina Maestre

Lidija Vranicar

Grant Timothy Lewis Smetham

Christophe Tarabout

Julian Richard Dixon

Daniel Martinez Lorente

Nicolas Fay

Fédéric Lacombe

Maria-Luisa Torres Salgado

Perrine Cambriel

Mercé Cardus Malaspina

Frederic Ben

John Batchelor

Pierre Bernard D'arbigny

Chris Ipsen Limited Dott

John Ipsen Limited Batchelor

A pharmaceutical composition for a sustained release of peptide therapeutics, in particular for a sustained release compatible with therapeutic treatments of at least two months. In an embodiment, the composition comprises lanreotide as an active agent, a hydrosoluble co-solvent, and water with the pH of the composition being from 4.0 to 7.5.

Pharmaceutical composition for a sustained release of lanreotide

A process for the preparation of injectable pharmaceutical compositions for the sustained release of somatostatin analogs and compositions prepared according to the process. The process may comprise lyophilizing a mixture of lanreotide acetate and acetic acid to form a lyophilizate and hydrating the lyophilizate, wherein the lyophilization is performed only once.

Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs

The present invention relates to a parenteral, sustained and controlled release, semisolid formulation comprising an end-capped oligomer and at least one active substance without any supplementary viscosity reducing agent or excipient.

Sustained release formulations comprising very low molecular weight polymers

The present invention relates to novel octapeptide compounds of general formula (I): H-2-Nal-cyclo(Cys-Tyr-AA-Lys-Val-Cys)-Thr-NH. Since these products have a good affinity for certain somatostatin receptor subtypes, they are particularly advantageous for treating pathological states or diseases in which one (or more) somatostatin receptor(s) is (are) involved. These compounds furthermore have physiochemical properties that make it possible to envisage them in diverse solutions for the formulation of medicaments, for example as a pharmaceutically acceptable carrier. The invention also relates to pharmaceutical compositions containing said products and to the use thereof for the preparation of a medicament.

Octapeptide compounds derived from somatostatin and the therapeutic use thereof

The invention relates to a process for the preparation of injectable pharmaceutical compositions for the sustained release of somatostatin analogues and to pharmaceutical compositions prepared according to the process. In a preferred aspect the process comprises the steps of combining lanreotide acetate and acetic acid, lyophilizing the resulting mixture only once, and hydrating the lyophilizate. Acetic acid may be added to a desired pH during the final step of the process.

The present invention relates to novel octapeptide compounds of general formula (I),R-AA-cyclo(AA-Tyr-D-Trp-AA-Val-Cys)-Thr-NH&#x2003;&#x2003;(I)As these products have a good affinity for certain sub-types of somatostatin receptors, they are particularly useful for treating the pathological states or diseases in which one (or more) of the somatostatin receptors is (are) involved. The invention also relates to pharmaceutical compositions containing said products and their use for the preparation of a medicament.

Octapeptide compounds and therapeutic use thereof

The present invention relates to pharmaceutical compositions for the controlled and sustained release of active substance comprising a biodegradable polymer or copolymer. Furthermore, the invention relates to pharmaceutical compositions for the controlled and sustained release of at least one active substance such as peptides or hormones and analogs thereof and the manufacturing process of such pharmaceutical compositions.

Sustained release formulations comprising GNRH analogues

The present invention relates to the use of a system composed of a base and of a sulphonamide, as a catalyst for the ring-opening (co)polymerization of lactones. The present invention also relates to novel sulphonamides and to a process for the ring-opening (co)polymerization of lactones comprising the use of sulphonamides in combination with a base as a catalytic system.

Catalytic systems for the ring-opening (co)polymerization of lactones

The use of a catalytic ring-opening lactide and glycolide (co)oligomerization system consisting of a strongly acidic ion-exchange resin-type polymeric catalyst and a (co)oligomerization additive, and a lactide and glycolide (co)oligomerization method using said catalytic system, are disclosed.

Use of a catalytic system for lactide and glycolide (co) oligomerization

The invention concerns a device for injecting a solid medicine () comprising a body () inside which moves along a general forward moving axis (X-X) a bevelled () needle () wherein is introduced the medicine (), said injection device () further comprising retaining means for preventing the medicine from falling () prior to being injected. The invention is characterized in that the medicine () is retained through an elastic deformation imparted to the needle () by the retaining means or by an elastic deformation of the retaining means themselves, or still by the combined flexibility of those two means.

Device for injecting a pharmaceutical active principle

A liquid or semi-solid formulation of botulinum toxin for the preparation of a medicament intended to treat a disorder characterized by bladder spasms (e.g. urinary incontinence due to unstable bladder or unstable detrusor sphincter, voiding complications due to detrusor overactivity or unstable detrusor sphincter, urinary retention secondary to spastic sphincter or hypertrophied bladder neck and neurogenic bladder dysfunction secondary to Parkinson's disease, spinal cord injury, stroke or multiple sclerosis or characterized by a spasm reflex), wherein said medicament is for administration by infusion into the bladder or by other methods that do not involve injection into the bladder wall.

Botulinum toxin treatment

The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefore comprising said analogues.

GLP-1 pharmaceutical compositions

The invention relates to a device which is used to inject an implant () into tissues (). The inventive device is characterized in that it comprises: a main hollow body (') having a hollow needle (&#x2032;) fixed thereto, into which the implant () is introduced; a secondary body (&#x2032;) which is disposed coaxially inside the main body (&#x2032;) and which surrounds the needle (&#x2032;); and a plunger rod (&#x2032;) which can slide coaxially inside the hollow needle (&#x2032;). The injection device (&#x2032;) is arranged such that: (i) when it is pressed against the tissues (), the main body (&#x2032;) slides along the length of the secondary body (&#x2032;) from a proximal position to a distal position such that the needle (&#x2032;) can penetrate the tissues (), whereby the movement of the main body (&#x2032;) is accompanied by the concomitant movement of the plunger rod (&#x2032;); and (ii) the plunger rod (&#x2032;) remains fixed and maintains the implant () at the required depth in the tissues () until the needle (&#x2032;) is removed therefrom when the main body (&#x2032;) is returned from the distal position to the proximal position.

Device for the injection of a solid or semi-solid implant

A catalytic lactide and glycolide copolymerization system comprising a trifluoromethane sulfonate as a catalyst and copolymerization additive and a copolymerization process.

Catalytic lactide and glycolide (co)polymerization system

The invention features a method of administering one or more therapeutic agents to a patient and delivering said agent or agents continuously over an extended period of time, said method comprising: obtaining a pharmaceutical composition including a peptide carrier, one or more therapeutic agents, and up to 30 percent, by weight, of a pharmaceutically acceptable, soluble, monomeric carrier; and parenterally administering said pharmaceutical composition to a subject by injection, wherein said composition automatically forms a gel after interaction with the patient's bodily fluids and releases said peptide carrier and said agent or agents continuously within the patient over an extended period.

Sustained release drug formulations containing a carrier peptide

Growing community of inventors

Barcelona, Spain

Roland Cherif-Cheikh